Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 25, 2026
Why Is SelectQuote (SLQT) Stock Down -33.33% Today?

Why Is SelectQuote (SLQT) Stock Down -33.33% Today?

Key Takeaways

  • SLQT shares plunged roughly 33.33% intraday, dropping from a prior close of $0.78 to about $0.52.
  • The selloff followed fourth-quarter fiscal 2026 earnings that missed expectations on both revenue and earnings per share.
  • Investors reacted most strongly to weaker-than-expected fiscal 2027 guidance, which came in well below Wall Street's consensus.
  • The company swung to a quarterly net loss of $16.8 million, versus net income of $12.9 million a year earlier.
  • Traders are now watching whether the stock can hold above its 52-week low and how analysts adjust estimates following the guidance cut.

Opening Summary

SelectQuote, Inc. (SLQT), a technology-enabled direct-to-consumer insurance distribution and healthcare services platform, saw its stock crater in Tuesday's session after reporting fourth-quarter and full-year fiscal 2026 results. The company, which operates three core business lines — SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life — posted revenue of $321.7 million for the quarter, down from $345.1 million a year earlier, while swinging to a net loss of $16.8 million. Shares tumbled approximately 33.33%, falling from a prior close of $0.78 to around $0.52, as the market digested both the top- and bottom-line misses and a softer-than-anticipated outlook for the coming year.

Earnings Results and Guidance Disappoint

The primary catalyst behind the sharp decline was a quarterly earnings report that fell short of analyst expectations. SelectQuote's fourth-quarter revenue of $321.7 million came in below the consensus estimate of roughly $345 million, while its loss per share of $0.19 was wider than the loss of about $0.15 to $0.16 that Wall Street had modeled. The results marked a notable reversal from the prior-year period, when the company had recorded net income of $12.9 million.

For the full fiscal year 2026, revenue totaled approximately $1.6 billion with net income of $62.2 million and adjusted EBITDA of $109.1 million. However, the headline numbers were overshadowed by forward-looking commentary, as management projected fiscal 2027 revenue of $1.35 billion to $1.45 billion — well below the roughly $1.65 billion analysts had been expecting — alongside adjusted EBITDA guidance of $90 million to $115 million.

Guidance Cut Weighs on Sentiment

Markets tend to react more forcefully to guidance than to backward-looking results, and that dynamic was on full display in SLQT. The company's fiscal 2027 revenue outlook implied a meaningful step down from the just-completed fiscal year, a signal that investors interpreted as reflecting ongoing pressure in the Medicare Advantage distribution market. Management has repeatedly cited "turbulent" industry conditions as insurance carriers adjust benefits and optimize volumes, and the conservative forecast reinforced concerns that these headwinds could persist.

Against that backdrop, the company's Senior segment reported a 12% year-over-year decline in quarterly revenue to $72.5 million, while Healthcare Services revenue fell 10% to $193.5 million. Submitted and approved Medicare Advantage policies both declined double digits in the quarter, a trend that contributed to the cautious near-term outlook.

Market Context and Trading Activity

The magnitude of the move reflected heavy selling pressure in a thinly traded, low-priced stock, which can amplify percentage swings. SLQT has a relatively small market capitalization — roughly $139 million prior to Tuesday's decline — and its shares trade at a low nominal price, factors that tend to produce outsized volatility on catalyst-driven days. The decline pushed the stock toward the lower end of its 52-week range and below key short-term moving averages, underscoring the technical damage inflicted by the report.

The move was largely company-specific rather than a reflection of broader market weakness, as the insurance and healthcare-services sectors did not experience a comparable drawdown. Rather, the earnings-driven move represented a repricing of the stock's fundamentals following the disappointing results and reduced forward outlook.

What Comes Next for SLQT

Looking ahead, investors will focus on whether the company can deliver on its stated goal of compounding operating cash flow, which management expects to approximately double to more than $60 million in fiscal 2027, with free cash flow of around $50 million. The company also highlighted technology-enabled efficiencies expected to drive more than $30 million in annual expense savings.

Key risks remain, however. SelectQuote's reliance on a limited number of insurance carrier partners, changes in Medicare Advantage plan design and commissions, and broader regulatory developments in the health insurance market all represent potential sources of uncertainty. Traders will also watch for any analyst estimate revisions and rating changes following the guidance cut, as well as the company's progress scaling its SelectRx pharmacy and healthcare services platform during the next Medicare annual enrollment period.

Trending AI Robots

For traders seeking a data-driven edge amid volatile single-stock moves, Tickeron's Trending AI Robots page offers a curated look at its strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a way to explore systematic approaches that adapt to shifting market environments. Explore the Trending AI Robots page to see which strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SLQT

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


SLQT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SLQT turned positive on July 27, 2026. Looking at past instances where SLQT's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 18, 2026. You may want to consider a long position or call options on SLQT as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SLQT advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 149 cases where SLQT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SLQT moved out of overbought territory on August 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where SLQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

SLQT moved below its 50-day moving average on August 24, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SLQT broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SLQT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.356) is normal, around the industry mean (6.907). SLQT's P/E Ratio (145.000) is considerably higher than the industry average of (37.767). SLQT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.772). SLQT's Dividend Yield (0.000) is considerably lower than the industry average of (0.013). P/S Ratio (0.090) is also within normal values, averaging (3.477).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are eHealth (NASDAQ:EHTH).

Industry description

Insurance brokers sell, solicit, or negotiate insurance for compensation. General insurance brokers mostly cater to insurances on car, house etc. (versus life). Brokers are also often instrumental in helping small employers find health insurance, particularly in more competitive markets. Additionally, brokers may also provide risk assessments, insurance consulting services, insurance-related regulatory and legislative update services. Some of the major names in this industry include Marsh & McLennan Companies, Inc., Aon plc and Verisk Analytics Inc.

Market Cap

The average market capitalization across the Insurance Brokers/Services Industry is 16.65B. The market cap for tickers in the group ranges from 377.24K to 92.9B. MRSH holds the highest valuation in this group at 92.9B. The lowest valued company is TIRX at 377.24K.

High and low price notable news

The average weekly price growth across all stocks in the Insurance Brokers/Services Industry was 7%. For the same Industry, the average monthly price growth was 29%, and the average quarterly price growth was 34%. EZRA experienced the highest price growth at 37%, while ZBAO experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Insurance Brokers/Services Industry was -18%. For the same stocks of the Industry, the average monthly volume growth was -11% and the average quarterly volume growth was 54%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 70
P/E Growth Rating: 67
Price Growth Rating: 49
SMR Rating: 72
Profit Risk Rating: 82
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
SLQT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a technology-enabled, direct-to-consumer distribution platform that provides consumers with a transparent and convenient venue to shop for complex senior health, life and auto & home insurance policies from a curated panel of insurance carriers

Industry InsuranceBrokersServices

Profile
Details
Industry
N/A
Address
6800 West 115th Street
Phone
+1 913 599-9225
Employees
4367
Web
http://www.selectquote.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.
Why Is SelectQuote (SLQT) Stock Down -33.33% Today?